Circulating soluble cytokine receptors and colorectal cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 1, 2014, Pages 179-188

  Ho, Gloria Y F ^a   Wang, Tao ^a   Zheng, Siqun L ^b   Tinker, Lesley ^c   Xu, Jianfeng ^b   Rohan, Thomas E ^a   Wassertheil Smoller, Sylvia ^a   Xue, Xiaonan ^a   Augenlicht, Leonard H ^a   Peters, Ulrike ^c,d   Phipps, Amanda I ^c   Strickler, Howard D ^a   Gunter, Marc J ^e   Cushman, Mary ^f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; ESTRADIOL; INSULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECEPTORS, CYTOKINE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892734096     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0545     Document Type: Article

References (26)

1. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-9.
2. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93.
3. Levine SJ. Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 2008;283:14177-81.
4. Yang Y, Bin W, Aksoy MO, Kelsen SG. Regulation of interleukin-1beta and interleukin-1beta inhibitor release by human airway epithelial cells. Eur Respir J 2004;24:360-6.
5. Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterol 2000;47:57-70.
6. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008;123:1133-40.
7. Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, et al. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 2012 72:3029-37.
8. Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterol 2011;140:799-808.
9. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63:321-9.
10. Kohno T, Brewer MT, Baker SL, Schwartz PE, King MW, Hale KK, et al. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A 1990;87:8331-5.
11. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl Acad Sci U S A 1992;89:4845-9.
12. Knupfer H, Preiss R. sIL-6R: more than an agonist? Immunol Cell Biol 2008;86:87-91.
13. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 2000;59 Suppl 1:i60-4.
14. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis C, et al. Implementation of the Women's Health Initiative Study Design. Ann Epidemiol 2003;13:S5-17.
15. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008;17:921-9.
16. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 2008;68:329-37.
17. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101: 48-60.
18. Luminex. xMAP Technology. [cited 2013 October 8]; Available from: http://www.luminexcorp.com/TechnologiesScience/xMAPTechnology/
19. Kaplan RC, Ho GY, Xue X, Rajpathak S, Cushman M, Rohan TE, et al. Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomarkers Prev 2007;16: 1291-3.
20. Agalliu I, Xue X, Cushman M, Cornell E, Hsing AW, Kaplan RC, et al. Detectability and reproducibility of plasma levels of chemokines and soluble receptors. Results Immunol 2013;3:79-84.
21. Ho GY, Xue X, Cushman M, McKeown-Eyssen G, Sandler RS, Ahnen DJ, et al. Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. J Natl Cancer Inst 2009;101:1650-4.
22. Self SG, Prentice RL. Asymptotic distribution theory and efficiency results for case-cohort studies. Ann Stat 1988;16:64-81.
23. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-72.
24. Fernandez-Botran R, Crespo FA, Sun X. Soluble cytokine receptors in biological therapy. Expert Opin Biol Ther 2002;2:585-605.
25. Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut 2005;54:488-95.
26. Okugawa Y, Miki C, Toiyama Y, Yasuda H, Yokoe T, Saigusa S, et al. Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer. Br J Cancer 2010;103: 787-95.